In terms of disease severity, our subgroup analysis showed no significant difference in circulating ANGPTL8 levels between NAFLD patients and controls when the corresponding studies reported the NAFLD severity either as mild or as moderate-to-severe (Figure 5). This evidence concerns the gene ANGPTL8 and metabolic dysfunction-associated steatotic liver disease.